Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 3, 2026Journal of Clinical Pathology

MYD88 gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

SNSingh NairMontefiore Medical CenterTHTeresa S HyunUniversity of WashingtonKNKikkeri N. NareshUniversity of Washington

Discussion

Loading...

Member takes

Implication

This review details MYD88 mutations and their clinical significance in lymphoid malignancies, highlighting implications for diagnosis and treatment.

Key Points

  • The aim is to explore the molecular mechanisms and clinical relevance of MYD88 mutations in lymphoid malignancies.
  • Summarized molecular biology of MYD88 and its role in signal transduction.
  • Discussed clinical implications, including diagnostic and therapeutic aspects.
  • Reviewed detection methodologies like allele-specific PCR and next-generation sequencing.
  • L265P mutation found in over 90% of lymphoplasmacytic lymphoma cases.
  • MYD88 mutation status serves as a diagnostic biomarker for differentiating lymphoid malignancies.
  • The L265P mutation influences treatment responses to BTK inhibitors, depending on co-occurring mutations.

Cite This Study

Nair et al. (2026) studied this question.

synapsesocial.com/papers/69cf5d4e5a333a821460afabhttps://doi.org/10.1136/jcp-2026-210690
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans2014 · 60 citations
  2. 2Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance2017 · 123 citations
  3. 3Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies2021 · 16 citations
  4. 4Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia2014 · 390 citations
  5. 5Diagnostic next-generation sequencing to detect MYD88 L265P in Lymphoplasmacytic lymphoma compared to ddPCR2025 · 4 citations